Literature DB >> 1538121

Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.

A Rashid1, H Auchincloss, J Sharon.   

Abstract

GK1.5 is a rat mAb that recognizes the mouse CD4 Ag. It has been shown to deplete CD4+ cells in vivo and to be immunosuppressive. To evaluate the effect of the C region of this antibody in achieving cell depletion, chimeric antibodies, each having the rat GK1.5 V regions and one of the four mouse IgG C region isotypes, were compared with the native rat antibody. The chimeric antibodies and the native antibody were tested for their ability to mediate in vitro C-dependent cytotoxicity, in vivo cell depletion, and prolongation of allogeneic skin graft survival and suppression of alloantibody production. In vitro C-dependent cytotoxicity assays revealed that rat IgG2b and the chimeric antibodies containing mouse IgG2a, mouse IgG2b, and mouse IgG3 were effective in lysing CD4+ lymphocytes whereas mouse IgG1 was ineffective. In vivo studies of CD4+ cell depletion showed that mouse IgG2a, rat IgG2b, and mouse IgG2b were effective isotypes, mouse IgG1 was less effective, and mouse IgG3 did not deplete CD4+ cells. A correlation was found between the ability of an isotype to deplete CD4+ cells in vivo and its ability to prolong the survival of skin allografts and to suppress alloantibody production. The nondepleting mouse IgG3 was ineffective in these assays. Overall the most effective mouse isotype was IgG2a which was as effective as rat IgG2b. These results indicate 1) that syngeneic isotypes of mAb can cause cell depletion and consequently the prolongation of allograft rejection and suppression of alloantibody production; 2) that not all isotypes are equally effective; and 3) that the ability of a given isotype to deplete cells in vivo does not correlate with its ability to mediate C-dependent lysis in vitro. Our results are consistent with the hypothesis that in vivo depletion of cells is mediated by opsonization and binding through the FcR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538121

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

2.  Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.

Authors:  Yuki Iwayanagi; Tomoyuki Igawa; Atsuhiko Maeda; Kenta Haraya; Naoko A Wada; Norihito Shibahara; Ken Ohmine; Takeru Nambu; Genki Nakamura; Futa Mimoto; Hitoshi Katada; Shunsuke Ito; Tatsuhiko Tachibana; Kou-ichi Jishage; Kunihiro Hattori
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

3.  The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Qi Wang; Catherine E Costello; Joseph Zaia; Barbara A Seaton; Jacqueline Sharon
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

4.  Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.

Authors:  J A Smith; J Y Tso; M R Clark; M S Cole; J A Bluestone
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

5.  Engagement of two distinct binding domains on CCL17 is required for signaling through CCR4 and establishment of localized inflammatory conditions in the lung.

Authors:  Sandra Santulli-Marotto; Ken Boakye; Eilyn Lacy; Sheng-Jiun Wu; Jennifer Luongo; Karl Kavalkovich; Ana Coelho; Cory M Hogaboam; Mary Ryan
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

6.  A CD74-dependent MHC class I endolysosomal cross-presentation pathway.

Authors:  Genc Basha; Kyla Omilusik; Ana Chavez-Steenbock; Anna T Reinicke; Nathan Lack; Kyung Bok Choi; Wilfred A Jefferies
Journal:  Nat Immunol       Date:  2012-02-05       Impact factor: 25.606

7.  Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.

Authors:  Atsuhiko Maeda; Yuki Iwayanagi; Kenta Haraya; Tatsuhiko Tachibana; Genki Nakamura; Takeru Nambu; Keiko Esaki; Kunihiro Hattori; Tomoyuki Igawa
Journal:  MAbs       Date:  2017-04-07       Impact factor: 5.857

8.  Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.

Authors:  Tomoyuki Igawa; Atsuhiko Maeda; Kenta Haraya; Tatsuhiko Tachibana; Yuki Iwayanagi; Futa Mimoto; Yoshinobu Higuchi; Shinya Ishii; Shigero Tamba; Naoka Hironiwa; Kozue Nagano; Tetsuya Wakabayashi; Hiroyuki Tsunoda; Kunihiro Hattori
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.